Introduction {#s1}
============

In recent years, more than 70 distinct genomic regions have been identified in which single nucleotide polymorphism (SNP) markers show reproducible association with type 2 diabetes mellitus (T2DM) at genome-wide statistical significance (*P* \< 5 × 10^−8^) ([@B1]--[@B17]). Most of these variants were discovered by genome-wide association studies (GWAS) in European populations, and their effects are best characterized in populations of European ancestry. Studies in other ethnic groups suggest that effects on T2DM are similar to those seen in Europeans for most variants ([@B18],[@B19]), but clear examples of heterogeneity in effects have been observed ([@B8],[@B10],[@B20]). There is limited information on the role of these established variants in populations at high risk for T2DM or on the extent to which differences in allele frequencies at these variants account for differences in population risk. In the present study, we analyze 63 established T2DM-susceptibility variants in Pima Indians, an American Indian population in whom the prevalence of T2DM is extraordinarily high ([@B21]).

Research Design and Methods {#s2}
===========================

Participants {#s3}
------------

Subjects were participants in a longitudinal study conducted in the Gila River Indian Community in central Arizona, where most residents are Pima Indians ([@B21]). The present study consisted of 3,421 individuals whose self-reported heritage was full Pima, Tohono O'odham, or a mixture of these closely related tribes and who had DNA available. These individuals constituted 1,951 sibships. There were 1,964 women and 1,457 men; mean ± SD age at last examination was 40.6 ± 16.5 years. Height and weight were measured, and a 75-g oral glucose tolerance test was administered; diabetes was diagnosed in 1,615 individuals (47.2%) according to 1997 American Diabetes Association criteria ([@B22]), i.e., 2-h postload plasma glucose ≥11.1 mmol/L, fasting plasma glucose ≥7.0 mmol/L, or a diagnosis during routine clinical care.

A subset of individuals participated in detailed physiologic studies to assess metabolic predictors of T2DM. Body composition was measured by hydrodensitometry or by DEXA, as previously described ([@B23]), in 405 nondiabetic full-heritage Pimas (172 women and 233 men; mean ± SD age 26.7 ± 6.1 years). Insulin sensitivity was measured in these 405 individuals by the hyperinsulinemic-euglycemic clamp ([@B23]). Insulin was infused at physiologic levels (∼130 µmol/L), and glucose was infused to maintain euglycemia. Rate of glucose uptake, normalized to estimated metabolic body size (EMBS), was taken as a measure of insulin sensitivity (*M*) (milligrams per kilogram EMBS per minute). Insulin secretion was measured as the acute insulin response (microunits per milliliter) 3--5 min after a 25-g intravenous glucose challenge ([@B23]) in 292 individuals (105 women and 187 men; mean ± SD age 26.7 ± 6.1 years) with normal glucose tolerance (2‑hour postload glucose \<7.8 mmol/L).

Genotyping {#s4}
----------

A sentinel SNP for each region was selected for genotyping from previously reported GWAS ([@B1]--[@B17]). Two SNPs were selected for *KCNQ1* and *CDC123,* where two distinct sets of variants have been described. In addition, 45 ancestry-informative markers ([@B24]) were genotyped for estimation of the individual proportion of European heritage ([@B25]). Genotyping was conducted by the SNPplex method (Life Technologies, Carlsbad, CA) or the BeadXpress system (Illumina, San Diego, CA) according to the manufacturer's instructions. Results for 18 SNPs were reported previously ([@B20],[@B26]--[@B29]). They are included here for a more complete characterization of the effects of established T2DM loci.

Association with T2DM and Related Traits {#s5}
----------------------------------------

Association between genotype and T2DM at the last research examination was analyzed by a logistic regression model, which was fit by the generalized estimating equation procedure to account for sibship. Genotype was coded as a numeric variable representing number of risk alleles as defined in previous GWAS. Thus, an odds ratio (OR) \>1 indicates association in the same direction as the established association and an OR \<1 indicates association in the opposite direction. Continuous variables were analyzed with a linear mixed model in which genotype and other covariates were fixed effects and sibship was a random effect. The logarithm of each variable was analyzed, and the regression coefficient was exponentiated to obtain the effect per copy of the T2DM risk allele, expressed as a multiplier.

For assessment of whether associations in Pimas were consistent with those in Europeans, ORs were compared by the Cochran Q test of homogeneity, and heterogeneity was quantified by the *I*^2^ measure ([@B30]). ORs for Europeans were taken from previous publications ([@B1],[@B2],[@B8],[@B9],[@B14]--[@B17],[@B31]--[@B40]). For assessment of whether GWAS-defined risk alleles contribute in aggregate to T2DM in Pimas, a multiallelic genetic risk score (GRS) was created by summing the number of risk alleles over all loci. To avoid reduction in sample size resulting from missing data at a few loci, we calculated the probability that an individual was of each possible genotype for each missing value from the genotypes in the individual's relatives using MLINK ([@B41]); these probabilities were used in calculating the GRS.

To test for heterogeneity across all loci, we combined *P* values derived from the heterogeneity test for individual SNPs by constructing a signed *Z* score. The *Z* score was computed for each SNP as *Z*~i~ = sign\[ln(OR~EUi~) − ln(OR~PIi~)\]Φ^−1^(*P*~heti~/2), where OR~EUi~ represents the OR for the ith SNP in Europeans, OR~PIi~ represents the corresponding OR in Pimas, *P*~heti~ is the *P* value for heterogeneity, and Φ^−1^ represents the inverse of the cumulative normal probability function. The sum of the *Z* scores across all SNPs divided by the square root of the number of SNPs (*Z*\*) was used to calculate a *P* value for the null hypothesis of homogeneity across all markers ([@B42]). If *Z*\* is negative, it indicates that ORs on average are weaker in Pimas than in Europeans, whereas if *Z*\* is positive it indicates that ORs are stronger in Pimas.

Differences in Allele Frequencies {#s6}
---------------------------------

Frequency of the risk allele was estimated by maximum likelihood methods using the ILINK program to account for family membership ([@B41]). Data for these 63 SNPs were obtained from the International HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/>) or, if not available from HapMap, from the 1000 Genomes Project (<http://www.1000genomes.org/>). For comparison of allele frequencies with other major continental ethnic groups, data were obtained for individuals of European ancestry from Centre d'Etude du Polymorphisme Humain families in Utah (CEU), for East Asians from Han Chinese in Beijing (CHB), and for Africans from Yoruba in Ibadan, Nigeria (YRI), HapMap populations. The likelihood ratio test was used to test significance of the difference in risk allele frequency in Pimas (*f*~R-Pima~) with that in each HapMap population (*f*~R-CEU~, *f*~R-CHB~, and *f*~R-YRI~). For assessment of whether T2DM risk alleles were systematically higher in one population than in another, the mean of the GRS (μ~GRS~) was compared between populations.

For a more general comparison of genetic distance between Pimas and other populations, the coancestry coefficient (*F*~ST~) was calculated across all T2DM-susceptibility variants by the method of moments ([@B43]). Since interpretation of *F*~ST~ is most straightforward when sample sizes are equal, Pima allele frequencies used in these calculations were derived from a random sample of equal effective size to the corresponding HapMap population; effective sample size was estimated by the method of Yang et al. ([@B44]). For comparison of *F*~ST~ calculated across the T2DM markers with its genomic expectation, random markers were selected from a GWAS in Pimas ([@B45]). Since SNP characteristics may have influenced detection of the T2DM markers, each T2DM-associated SNP was matched to potential random SNPs by minor allele frequency in CEU, base pair type, and chromosome type (autosomal vs. X chromosome); to avoid selecting markers highly concordant with those for susceptibility to T2DM, we excluded a 2-Mb region on either side of the sentinel SNP from this selection. A total of 294,467 potentially matching random SNPs were thus identified. Significance of the difference between *F*~ST~ at T2DM variants and *F*~ST~ at random markers was calculated by a bootstrap procedure in which one random marker was selected for each T2DM variant in each iteration.

Excess Population Prevalence Attributable to Allele Frequency Differences {#s7}
-------------------------------------------------------------------------

For quantification of the extent to which differences in T2DM risk allele frequencies can explain the difference in T2DM prevalence between Pimas and Europeans, standard multivariable epidemiologic methods for calculation of attributable fraction ([@B46]) were modified to calculate the genetic attributable fraction (GAF) for the population difference in prevalence. We define this as the proportion of the excess T2DM prevalence in a high-risk "target" population compared with a low-risk "reference" population attributable to differences in risk allele frequency. If *P*~0~ represents prevalence in the reference population (e.g., Europeans) and *P*~1~ is prevalence in the target population (e.g., Pimas), thenwhere *P*~1adj~ is prevalence in the target population adjusted for the allele frequency differences (i.e*.,* prevalence if the target population had the same risk allele frequencies as the reference population) (Eq. 1). Data from non-Hispanic white participants in the oral glucose tolerance subset of the U.S. National Health and Nutrition Examination Survey (NHANES) 2005--2010 were used for the reference population (<http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm>). These data were from 3,282 individuals age 12--84 years (1,585 women, 1,697 men; mean ± SD age 46.8 ± 20.1 years); 523 individuals (15.9%) had diabetes. These data were combined with Pimas of the same age range for calculation of GAF.

If genotypic data for all markers were available for all individuals, the quantities needed to calculate GAF could be derived from multivariable logistic regression. However, such data are not readily available for NHANES participants, so we developed an approximation that uses allele frequency and OR estimates from other sources. Adjusted prevalence in each population was obtained from the following logistic regression equation: logit (prevalence) = α~0~ + α~1~*I* + γ~1~(cov~1~) + . . . γ~m~(cov~m~), where *I* is an indicator variable that takes the value of 0 for the reference population and 1 for the target population and γ~1~--γ~m~ represent the coefficients corresponding to *m* covariates (centered at the mean values in the target population). Under an additive model with assumptions of Hardy-Weinberg equilibrium in both populations, independence among SNPs, and that the population OR changes as a function of the OR associated with each SNP and the difference in risk allele frequency, the expected value of α~1~, given that allele frequencies are the same as in the reference population, is as follows: α~1adj~ = α~1~ − Σ\[2β~i~(*f*~R1i~^2^ + *f*~R1i~\[1 − *f*~R1i~\] − *f*~R0i~^2^ − *f*~Roi~\[1 − f~Roi~\])\], where β~i~ is the logarithm of the OR for the ith SNP, *f*~R1i~ is the risk allele frequency in the target population, and *f*~R0i~ is the frequency in the reference population. For the present analyses, allele frequencies in the HapMap CEU population were taken as representative of the reference population. The values required for calculation of GAF (see Eq. 1) are as follows:Simulation studies suggest that estimates of GAF derived by this method provide a good approximation of those derived from a multivariable regression in which all data are available for all individuals ([Fig. 1](#F1){ref-type="fig"}). CIs and hypothesis tests for GAF were derived from a bootstrap procedure in which Pima, NHANES, and CEU populations were resampled and ORs were sampled from published values and standard errors.

![Simulations comparing the approximate method for estimation of GAF with the "true" GAF, estimated from a multivariable logistic regression model containing all SNPs. Simulations were conducted generating 100,000 individuals from a reference population and 3,000 individuals from a target population. Twenty-five pairs of susceptibility loci were generated from a distribution with allele frequency differences between target and reference populations given *F*~ST~ = 0.15 such that each locus was matched to another with the same minor allele frequency in each population. Phenotypes were generated with each locus contributing ∼0.15% to disease liability, along with a residual population effect such that the OR comparing the target with reference population was ∼10. The expected GAF was controlled by specifying the proportion of matched pairs for which the risk allele had a higher frequency in the target population for both members of the pair (e.g.*,* if for each matched pair of loci one has a higher frequency in the target population and the other has a higher frequency in the reference population, the expected GAF is ∼0, while if all loci have higher risk allele frequency in the reference population, expected GAF is ∼1). The true GAF was calculated from logistic regression models with all 103,000 individuals. For simulation of the situation in the present study, for the approximate method, allele frequencies for the reference population were calculated from a subset of 180 individuals and the prevalence estimates between populations from a subset of 3,000 individuals from the reference population. Six thousand replicate data sets were analyzed. Owing to chance variation in the simulation, both true and approximate GAF may be \<0 or \>1.](db141715f1){#F1}

RESULTS {#s8}
=======

Association with T2DM {#s9}
---------------------

Eight SNPs (rs17106184 in *FAF1*, rs7578597 in *THADA*, rs3923113 in *GRB14*, rs831571 in *PSMD6*, rs6808574 in *LPP*, rs1531343 in *HMGA2*, rs7957197 in *HNF1A*, and rs17782313 in *MC4R*) were nearly monomorphic (minor allele frequency \<0.01) in Pimas and were not analyzed for association. [Table 1](#T1){ref-type="table"} shows the association for each of the remaining 55 SNPs with T2DM in Pima Indians, along with the test for heterogeneity in ORs between Pimas and Europeans. Nine SNPs, those in *GCKR, ZBED3, CDKAL1, ZFAND3, KCNQ1, SPRY2, HMG20A, PRC1*, and *FTO*, had nominally significant associations (*P* \< 0.05) in Pimas in the same direction as the established association. The previously reported result with the *KCNQ1* SNP rs2237892 was the strongest association. Ten SNPs, in *IRS1, ADAMTS9, ARL15, ZFAND3, PTPRD, TCF7L2, MPHOSPH9, C2CD4A, SLC16A11*, and *DUSP9*, showed nominally significant heterogeneity between Pimas and Europeans. Nonetheless, ORs were in the same direction as the established association for 39 of the 55 SNPs.

###### 

Association of variants with T2DM in Pima Indians and comparison with association in Europeans

  Gene           SNP          Allele R/L   Pima freq.   Proportion of Pimas with Diabetes (*n*)   Pima Indians   Europeans      Heterogeneity      Ref.                                                                                                     
  -------------- ------------ ------------ ------------ ----------------------------------------- -------------- -------------- ------------------ ----------------------- ------ --------------------------------------------------- -------- ------------ ----
  NOTCH2         rs10923931   T/G          0.10         0.37 (27)                                 0.46 (540)     0.47 (2,622)   0.5803             0.94 (0.76--1.17)       0.09   1.13 (1.09--1.17)                                   63       0.0980       1
  PROX1          rs340874     C/T          0.35         0.49 (353)                                0.47 (1,488)   0.46 (1,388)   0.4563             1.05 (0.93--1.19)       0.57   1.07 (1.05--1.09)                                   0        0.7444       14
  GCKR           rs780094     C/T          0.95         0.47 (2,982)                              0.40 (278)     0.32 (7)       **0.0230**         **1.38 (1.04--1.81)**   0.59   1.06 (1.04--1.08)                                   71       0.0638       14
  BCL11A         rs243021     A/G          0.78         0.48 (1,987)                              0.46 (1,109)   0.41 (151)     0.1775             1.10 (0.96--1.28)       0.47   1.08 (1.06--1.10)                                   0        0.7630       2
  IRS1           rs7578326    A/G          0.91         0.45 (2,724)                              0.54 (517)     0.44 (27)      **0.0081**         **0.76 (0.62--0.93)**   0.65   1.11 (1.09--1.13)                                   **92**   **0.0003**   2
  PPARG          rs1801282    C/G          0.92         0.47 (2,758)                              0.45 (477)     0.37 (19)      0.3807             1.10 (0.89--1.37)       0.90   1.16 (1.09--1.23)                                   0        0.6649       31
  UBE2E2         rs7612463    C/A          0.97         0.46 (3,073)                              0.55 (191)     0.00 (4)       0.1080             0.76 (0.55--1.06)       0.87   1.05 (0.97--1.14)                                   71       0.0656       1
  ADAMTS9        rs4607103    C/T          0.62         0.45 (1,102)                              0.47 (1,432)   0.49 (418)     0.2405             0.93 (0.81--1.05)       0.81   1.09 (1.06--1.12)                                   **83**   **0.0155**   1
  ADCY5          rs11708067   A/G          0.50         0.47 (821)                                0.47 (1,594)   0.46 (807)     0.6991             1.02 (0.90--1.16)       0.78   1.12 (1.09--1.15)                                   47       0.1715       14
  IGF2BP2        rs4402960    T/G          0.17         0.52 (99)                                 0.46 (853)     0.47 (2,166)   0.6191             1.04 (0.89--1.21)       0.30   1.13 (1.10--1.16)                                   8        0.2976       32
  ST6GAL         rs16861329   C/T          0.44         0.46 (562)                                0.48 (1,576)   0.45 (979)     0.5209             1.04 (0.92--1.18)       0.88   1.02 (0.95--1.09)                                   0        0.7760       9
  MAEA           rs6815464    C/G          0.61         0.48 (1,278)                              0.46 (1,442)   0.46 (470)     0.4159             1.05 (0.93--1.19)       0.99   1.19 (1.04--1.36)                                   45       0.1761       8
  WFS1           rs10010131   G/A          0.98         0.47 (3,019)                              0.36 (92)      0.00 (1)       0.0590             1.59 (0.98--2.58)       0.67   1.12 (1.08--1.16)                                   51       0.1544       33
  TMEM154        rs6813195    C/T          0.51         0.48 (850)                                0.47 (1,635)   0.44 (800)     0.1850             1.08 (0.96--1.21)       0.72   1.08 (1.05--1.11)                                   0        0.9851       17
  ALR15          rs702634     A/G          0.99         0.46 (3,221)                              0.63 (77)      --- (0)        **0.0351**         **0.51 (0.27--0.95)**   0.71   1.05 (1.02--1.08)                                   **80**   **0.0240**   17
  ZBED3          rs4457053    G/A          0.36         0.52 (441)                                0.47 (1,481)   0.44 (1,346)   **0.0246**         **1.15 (1.02--1.31)**   0.26   1.08 (1.05--1.11)                                   3        0.3107       2
  SSR1           rs9505118    A/G          0.53         0.50 (877)                                0.46 (1,495)   0.44 (686)     0.0621             1.12 (0.99--1.27)       0.62   1.06 (1.03--1.09)                                   0        0.3651       17
  CDKAL1         rs7756992    G/A          0.32         0.52 (372)                                0.47 (1,352)   0.45 (1,448)   **0.0366**         **1.15 (1.01--1.30)**   0.28   1.22 (1.17--1.27)                                   0        0.3548       34
  POU5F1         rs3130501    G/A          0.61         0.47 (1,180)                              0.47 (1,570)   0.45 (536)     0.5962             1.03 (0.92--1.16)       0.73   1.06 (1.02--1.10)                                   0        0.6720       17
  ZFAND3         rs9470794    C/T          0.03         0.82 (3)                                  0.56 (179)     0.46 (3,038)   **0.0069**         **1.56 (1.13--2.16)**   0.12   0.98 (0.88--1.09)                                   **86**   **0.0073**   1
  DGKB-TMEM195   rs2191349    T/G          0.19         0.47 (117)                                0.46 (1,017)   0.47 (2,116)   0.9503             1.00 (0.86--1.16)       0.47   1.06 (1.04--1.08)                                   0        0.4150       14
  JAZF1          rs864745     T/C          0.78         0.48 (1,947)                              0.44 (1,003)   0.44 (137)     0.1250             1.13 (0.97--1.31)       0.50   1.10 (1.07--1.13)                                   0        0.7708       1
  GCK            rs4607517    A/G          0.34         0.46 (359)                                0.47 (1,504)   0.47 (1,359)   0.8376             0.99 (0.87--1.12)       0.19   1.07 (1.04--1.10)                                   36       0.2126       14
  GCC1-PAX4      rs6467136    G/A          0.29         0.46 (300)                                0.47 (1,315)   0.47 (1,629)   0.7316             0.98 (0.86--1.11)       0.50   1.00 (0.94--1.06)                                   0        0.7551       1
  KLF14          rs972283     G/A          0.38         0.52 (442)                                0.45 (1,415)   0.46 (1,121)   0.1854             1.09 (0.96 --1.24)      0.55   1.07 (1.04--1.10)                                   0        0.7865       2
  TP53INP1       rs896854     T/C          0.48         0.48 (736)                                0.47 (1,631)   0.45 (879)     0.2439             1.07 (0.95--1.21)       0.43   1.06 (1.03--1.09)                                   0        0.8455       2
  SLC30A8        rs13266634   C/T          0.91         0.47 (2,658)                              0.45 (520)     0.53 (33)      0.6870             1.04 (0.85--1.29)       0.76   1.14 (1.12--1.16)                                   0        0.4121       35
  GLIS3          rs7041847    A/G          0.66         0.48 (1,334)                              0.45 (1,468)   0.46 (377)     0.2742             1.07 (0.95--1.22)       0.55   1.04 (0.98--1.10)                                   0        0.6599       1
  PTPRD          rs17584499   T/C          0.10         0.29 (38)                                 0.42 (537)     0.48 (2,528)   **0.0081**         **0.75 (0.60--0.93)**   0.23   1.03 (0.94--1.13)                                   **86**   **0.0074**   1
  CDKN2B         rs10811661   T/C          0.94         0.47 (2,830)                              0.44 (362)     0.50 (10)      0.3518             1.13 (0.87--1.46)       0.80   1.22 (1.17--1.27)                                   0        0.5664       36
  CHCHD9         rs13292136   C/T          0.66         0.47 (1,445)                              0.47 (1,419)   0.43 (400)     0.4280             1.05 (0.93--1.19)       0.93   1.11 (1.07--1.15)                                   0        0.3891       2
  CDC123         rs10906115   A/G          0.57         0.46 (1,015)                              0.47 (1,504)   0.48 (605)     0.5695             0.96 (0.85--1.09)       0.64   1.07 (1.00--1.14)                                   53       0.1433       1
  CDC123         rs12779790   G/A          0.15         0.53 (89)                                 0.45 (711)     0.47 (2,260)   0.9526             1.00 (0.85--1.17)       0.23   1.11 (1.08--1.14)                                   41       0.1935       1
  VPS26A         rs1802295    T/C          0.25         0.43 (170)                                0.48 (1,126)   0.46 (1,667)   0.8955             1.01 (0.87--1.17)       0.35   1.04 (0.99--1.09)                                   0        0.7076       9
  HHEX           rs1111875    C/T          0.39         0.49 (467)                                0.47 (1,540)   0.45 (1,176)   0.2025             1.08 (0.96--1.22)       0.58   1.16 (1.09--1.23)                                   2        0.3130       37
  TCF7L2         rs7903146    T/C          0.08         0.53 (27)                                 0.47 (397)     0.46 (2,590)   0.6314             1.06 (0.84--1.35)       0.29   1.38 (1.32--1.44)                                   **78**   **0.0327**   38
  KCNQ1          rs231362     G/A          0.93         0.47 (2,673)                              0.43 (332)     0.49 (20)      0.2890             1.15 (0.89--1.47)       0.51   1.08 (1.06--1.10)                                   0        0.6453       2
  KCNQ1          rs2237892    C/T          0.51         0.52 (823)                                0.48 (1,643)   0.39 (803)     **9.4 × 10^−6^**   **1.31 (1.16--1.48)**   0.92   1.19 (1.11--1.28)                                   47       0.1713       39
  KCNJ11         rs5219       T/C          0.38         0.48 (505)                                0.47 (1,583)   0.45 (1,252)   0.3823             1.05 (0.94--1.19)       0.37   1.12 (1.08--1.16)                                   0        0.3386       40
  CENTD2         rs1552224    A/C          0.95         0.47 (2,987)                              0.39 (284)     0.89 (3)       0.0606             1.33 (0.99--1.78)       0.87   1.14 (1.11--1.17)                                   0        0.3167       2
  MNTR1B         rs1387153    T/C          0.11         0.44 (46)                                 0.47 (635)     0.47 (2,663)   0.9000             1.01 (0.84--1.22)       0.27   1.12 (1.07--1.17)                                   4        0.3084       2
  TSPAN8         rs7961581    C/T          0.01         --- (0)                                   0.31 (60)      0.47 (2,999)   0.0907             0.51 (0.24--1.11)       0.26   1.09 (1.06--1.12)                                   73       0.0563       1
  MPHOSPH9       rs4275659    C/T          0.44         0.47 (622)                                0.45 (1,651)   0.50 (1,031)   0.2839             0.94 (0.83--1.06)       0.67   1.06 (1.03--1.09)                                   **74**   **0.0497**   17
  SPRY2          rs1359790    G/A          0.64         0.48 (1,271)                              0.48 (1,431)   0.39 (425)     **0.0408**         **1.14 (1.01--1.29)**   0.73   1.11 (1.04--1.18)                                   0        0.7115       1
  C2CD4A         rs7172432    A/G          0.37         0.39 (428)                                0.47 (1,423)   0.48 (1,176)   **0.0252**         **0.86 (0.76--0.98)**   0.57   1.07 (1.01--1.13)                                   **89**   **0.0027**   1
  HMG20A         rs7178572    G/A          0.64         0.50 (1,343)                              0.44 (1,390)   0.45 (447)     **0.0480**         **1.13 (1.00--1.28)**   0.67   1.07 (1.02--1.12)                                   0        0.4054       9
  ZFAND6         rs11634397   G/A          0.56         0.45 (1,000)                              0.48 (1,614)   0.46 (601)     0.6605             0.97 (0.86--1.10)       0.64   1.06 (1.04--1.08)                                   47       0.1706       2
  AP3S2          rs2028299    C/A          0.06         0.54 (19)                                 0.49 (329)     0.46 (2,845)   0.3632             1.12 (0.88--1.42)       0.27   1.05 (1.01--1.09)                                   0        0.6118       9
  PRC1           rs8042680    A/C          0.99         0.47 (3,231)                              0.26 (49)      --- (0)        **0.0497**         **2.48 (1.00--6.12)**   0.26   1.07 (1.04--1.10)                                   70       0.0695       2
  FTO            rs8050136    A/C          0.14         0.67 (79)                                 0.48 (806)     0.46 (2,475)   **0.0116**         **1.23 (1.05--1.45)**   0.46   1.14 (1.07--1.21)                                   0        0.3812       1
  SRR            rs391300     C/T          0.83         0.46 (2,326)                              0.47 (904)     0.44 (83)      0.8485             0.99 (0.84--1.15)       0.63   1.02 (0.95--1.09)                                   0        0.6843       1
  SLC16A11       rs75493593   T/G          0.41         0.49 (527)                                0.47 (1,525)   0.45 (1,071)   0.2168             1.08 (0.96--1.22)       0.01   1.25 (1.18--1.32)[\*](#t1n1){ref-type="table-fn"}   **78**   **0.0328**   16
  TCF2           rs4430796    G/A          0.29         0.47 (295)                                0.50 (1,310)   0.44 (1,589)   0.0830             1.12 (0.99--1.28)       0.51   1.10 (1.05--1.15)                                   0        0.7855       15
  HNF4A          rs6017317    G/T          0.83         0.47 (2,229)                              0.47 (944)     0.40 (67)      0.6554             1.04 (0.88--1.22)       0.18   1.10 (1.02--1.19)                                   0        0.5178       1
  DUSP9          rs5945326    A/G          0.27         0.46 (473)                                0.49 (726)     0.46 (2,014)   0.7378             1.02 (0.91--1.15)       0.77   1.27 (1.18--1.37)                                   **89**   **0.0024**   2

Alleles are listed with the risk allele given first. The proportion of individuals with T2DM is given among those homozygous for the risk allele (RR), heterozygous individuals (LR), and those homozygous for the low-risk allele (LL). The OR is given per copy of the risk allele as defined in previous studies. Frequencies for Europeans are derived from the HapMap CEU population, and European ORs are derived from the reference. *I*^2^ represents the percentage of variance in the ORs attributable to heterogeneity between Pimas and Europeans, and *P*~het~ is the *P* value for the null hypothesis that the two ORs are equal. Results with nominal statistical significance (*P* \< 0.05) are shown in boldface type. Results in Pimas are adjusted for age, sex, birth year, and heritage. freq., frequency of the risk allele.

\*The risk allele for the *SLC16A11* variant rs75493593 is rare in Europeans, so the "global" OR is reported ([@B16]).

Associations with Metabolic Predictors of T2DM {#s10}
----------------------------------------------

Results for SNPs with nominally significant and directionally consistent associations with metabolic traits are shown in [Table 2](#T2){ref-type="table"}. Results for all SNPs are shown in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1715/-/DC1). The T2DM risk allele was associated with lower insulin secretion for SNPs in *PROX1, IGF2BP2, ZBED3, DGKB-TMEM195, GLIS3, CDC123, HHEX, KCNQ1*, and *MNTR1B*. The T2DM risk allele for SNPs in *IRS1, PPARG, MNTR1B, PRC1*, and *SRR* was associated with lower values of insulin sensitivity. Since the *MNTR1B* SNP was associated with both insulin secretion and total body insulin sensitivity, we further investigated its relationship with hepatic insulin sensitivity, measured in the clamp using radiolabeled glucose, and found that the risk allele was associated with lower sensitivity (*r* = −0.15, *P* = 0.002). The T2DM risk allele was significantly associated with higher percentage body fat for SNPs in *PRC1* and *ZFAND3*. When BMI was analyzed in the larger population, the T2DM risk alleles for variants in *GCK* and *FTO* were associated with significantly higher BMI (Supplemental Table 2).

###### 

Variants with significant (*P* \< 0.05) and directionally consistent associations with metabolic traits

  Associated with insulin secretion        Mean acute insulin response (µU/mL)   *P*   Eff (95% CI)   *r*                                                                
  ---------------------------------------- ------------------------------------- ----- -------------- ------------ ----------- ------------ -------- ------------------- -------
  PROX1                                    rs340874                              C/T   0.35           150 (26)     229 (141)   234 (113)    0.0121   0.87 (0.78--0.97)   −0.14
  IGF2BP2                                  rs4402960                             T/G   0.17           186 (7)      194 (63)    234 (176)    0.0272   0.85 (0.74--0.98)   −0.17
  ZBED3[\*](#t2n1){ref-type="table-fn"}    rs4457053                             G/A   0.36           209 (38)     199 (122)   249 (117)    0.0221   0.88 (0.80--0.98)   −0.16
  DGKB-TMEM195                             rs2191349                             T/G   0.19           175 (12)     190 (101)   248 (173)    0.0002   0.79 (0.70--0.89)   −0.24
  GLIS3                                    rs7041847                             A/G   0.66           203 (99)     223 (146)   276 (40)     0.0080   0.87 (0.78--0.96)   −0.16
  CDC123                                   rs12779790                            G/A   0.15           162 (7)      200 (56)    231 (204)    0.0382   0.85 (0.74--0.99)   −0.09
  HHEX                                     rs1111875                             C/T   0.39           179 (35)     224 (128)   238 (93)     0.0272   0.88 (0.79--0.99)   −0.12
  KCNQ1[\*](#t2n1){ref-type="table-fn"}    rs2237892                             C/T   0.51           180 (65)     231 (135)   249 (79)     0.0019   0.85 (0.77--0.94)   −0.20
  MNTR1B                                   rs1387153                             T/C   0.11           320 (2)      174 (41)    230 (235)    0.0405   0.82 (0.68--0.99)   −0.15
  Associated with insulin sensitivity      Mean M (mg/kg EMBS/min)               *P*   Eff (95% CI)   *r*                                                                
  Gene                                     SNP                                   R/L   Freq.          RR           LR          LL                                        
  IRS1                                     rs7578326                             A/G   0.91           3.48 (330)   3.71 (55)   4.16 (2)     0.0263   0.94 (0.88--0.99)   −0.12
  PPARG                                    rs1801282                             C/G   0.92           3.47 (331)   3.80 (58)   3.65 (5)     0.0087   0.93 (0.88--0.98)   −0.12
  MNTR1B                                   rs1387153                             T/C   0.11           2.56 (2)     3.40 (67)   3.55 (319)   0.0411   0.94 (0.89--1.00)   −0.11
  PRC1[\*](#t2n1){ref-type="table-fn"}     rs8042680                             A/C   0.99           3.51 (383)   4.52 (6)    --- (0)      0.0179   0.78 (0.63--0.96)   −0.12
  SRR                                      rs391300                              C/T   0.83           3.45 (291)   3.71 (92)   3.82 (10)    0.0028   0.94 (0.90--0.98)   −0.15
  Associated with Adiposity                Mean Percentage Body Fat (%)          *P*   Eff (95% CI)   *r*                                                                
  Gene                                     SNP                                   R/L   Freq.          RR           LR          LL                                        
  PRC1[\*](#t2n1){ref-type="table-fn"}     rs8042680                             A/C   0.99           32.2 (383)   24.0 (6)    --- (0)      0.0087   1.35 (1.08--1.68)   0.13
  ZFAND3[\*](#t2n1){ref-type="table-fn"}   rs9470794                             C/T   0.03           --- (0)      36.2 (16)   31.7 (378)   0.0314   1.14 (1.01--1.29)   0.12

Directionally consistent associations are those for which the T2DM risk allele is associated with lower insulin secretion, lower insulin sensitivity, or higher percentage body fat. R/L represents the risk and low-risk alleles for T2DM, respectively, based on previously published studies. RR, LR, and LL are the geometric means for each variable in individuals homozygous for the risk allele and heterozygous and homozygous for the low-risk allele, respectively. The logarithm of each variable was analyzed and the regression coefficient was exponentiated to obtain the effect (Eff) per copy of the T2DM risk allele, expressed as a multiplier. *R* is the correlation between the trait and the risk allele. Results for insulin secretion are adjusted for age, sex, heritage, insulin sensitivity, and percentage body fat. Results for insulin sensitivity are adjusted for age, sex, heritage, and percentage body fat. Results for percentage body fat are adjusted for age, sex, and heritage. Freq., frequency of the risk allele in Pimas.

\*Risk allele is significantly associated with T2DM in Pimas. (See [Table 1](#T1){ref-type="table"}.)

Multiallelic Association {#s11}
------------------------

Associations with the multiallelic GRS are shown in [Fig. 2](#F2){ref-type="fig"}. The sum of the number of risk alleles over all 55 SNPs was significantly associated with T2DM (OR 1.05 per copy of a risk allele, *P* = 6.2 × 10^−6^). There was also a strong association between a greater number of T2DM risk alleles and lower values of insulin secretion such that each copy of a risk allele was associated with a 4% decrease in insulin secretion (*P* = 4.1 × 10^−6^). There was little association with insulin sensitivity or percentage body fat. When alleles were weighted by the logarithms of the published ORs in constructing the GRS, similar results were obtained (data not shown). When BMI was analyzed, results were similar to those seen with percentage body fat, but the inverse association was statistically significant (lower by 0.4% per risk allele, *P* = 1.2 × 10^−5^) ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1715/-/DC1)). When the GRS was constructed using only the nine insulin secretion--associated SNPs, each risk allele was associated with a 13% decrease in insulin secretion; similarly, in a score constructed from the five insulin sensitivity SNPs, each risk allele was associated with a 7% decrease in insulin sensitivity ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1715/-/DC1)). The insulin secretion score was associated with T2DM (OR 1.09, *P* = 2.7 × 10^−4^); when these nine SNPs were excluded from the global GRS, the T2DM association was modestly attenuated (OR 1.04, *P* = 1.1 × 10^−3^).

![Relationship between the GRS across 55 loci and prevalence of T2DM, percentage body fat, insulin sensitivity, and insulin secretion in Pima Indians. The GRS is calculated as the number of risk alleles and shown in categories, plotted at the midpoint. Results for T2DM involve 3,247 individuals and are adjusted for age, sex, birth year, and heritage. Results for percentage body fat involve 384 individuals and are adjusted for age, sex, and heritage. Results for insulin sensitivity involve 384 individuals and are adjusted for age, sex, heritage, and percentage body fat. Results for insulin secretion involve 274 individuals and are adjusted for age, sex, heritage, percentage body fat, and insulin sensitivity. ORs calculated per copy of a risk allele. AIR, acute insulin response. eff, effect.](db141715f2){#F2}

Heterogeneity {#s12}
-------------

The test for heterogeneity in the effect on T2DM across all SNPs was statistically significant (*P* = 3.9 × 10^−5^) and negative in sign (*Z*\* = −4.12); this indicates that the effects of these SNPs are on average weaker in Pimas than in Europeans. When the 18 SNPs with nominally significant association with T2DM or significant heterogeneity were excluded, the effects of the GRS on T2DM (OR 1.04, *P* = 4.9 × 10^−4^) and insulin secretion (effect −4%, *P* = 8.0 × 10^−6^) remained significant, as did evidence for heterogeneity (*Z*\* = −2.82, *P* = 4.8 × 10^−3^).

Allele Frequency Differences between Pimas and Major Continental Populations {#s13}
----------------------------------------------------------------------------

The difference in frequency of the T2DM risk allele between Pimas and HapMap populations is shown for each locus in [Supplementary Fig. 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1715/-/DC1). The distribution of the GRS in each population is shown in [Fig. 3](#F3){ref-type="fig"}. Mean GRS in Pimas (68.4) was slightly but significantly lower than in CEU (69.2, *P* = 0.049); mean GRS in Pimas was also significantly lower than in YRI (73.7, *P* = 4.4 × 10^−38^) but higher than in CHB (66.6, *P* = 9.6 × 10^−5^). When loci were weighted by the logarithms of the ORs in constructing the GRS, results were similar, except that the contrast in mean GRS between Pimas and CEU was more pronounced (*P* = 1.2 × 10^−10^).

![Cumulative distribution of the GRS for T2DM in Pimas and in each of the HapMap populations (CHB, CEU, and YRI). In the left panel, the GRS was calculated as the sum of the number of risk alleles across all 63 loci, while in the right panel it is the sum of the number of risk alleles multiplied by log(OR), as determined in Europeans. Differences in the mean GRS (μ) between populations were compared in a mixed model in which population was a fixed effect and sibship was a random effect. *P* values for comparison of the GRS between populations are as follows: *P* = 0.049 (1.2 × 10^−10^) for Pimas and CEU, *P* = 9.6 × 10^−5^ (1.5 × 10^−4^) for Pimas and CHB, *P* = 9.4 × 10^−38^ (2.5 × 10^−72^) for Pimas and YRI, *P* = 9.7 × 10^−5^ (1.3 × 10^−22^) for CEU and CHB, *P* = 7.9 × 10^−13^ (5.4 × 10^−15^) for CEU and YRI, and *P* = 1.5 × 10^−23^ (5.7 × 10^−46^) for CHB and YRI, where the value in parentheses is for the GRS weighted by log(OR). Results involve 3,253 Pimas, 110 individuals for CEU, 84 individuals for CHB, and 111 individuals for YRI. (For HapMap populations, calculation was restricted to founders.)](db141715f3){#F3}

Genetic distances among populations across all 63 T2DM markers and across random markers are summarized in [Fig. 4](#F4){ref-type="fig"}. *F*~ST~ across these T2DM loci was 0.163 (95% CI 0.154, 0.173) between Pimas and CEU, 0.138 (0.125, 0.152) between Pimas and CHB, and 0.232 (0.221, 0.244) between Pimas and YRI. These values were not significantly different from those derived from matched sets of SNPs randomly selected across the genome: *F*~ST~ 0.158 (0.106, 0.209) between Pimas and CEU (*P* = 0.83 for difference in *F*~ST~), 0.129 (0.078, 0.180) between Pimas and CHB (*P* = 0.74), and 0.241 (0.173, 0.309) between Pimas and YRI (*P* = 0.80). Thus, differences in allele frequency are generally similar to those expected given genetic distances between populations.

![Dendrogram summarizing genetic distances between Pima Indians and HapMap populations at 63 T2DM susceptibility loci and at randomly selected genomic markers. Genetic distance was calculated as *F*~ST~, and the dendrogram was generated using PHYLIP. *F*~ST~ is calculated as the mean value from a bootstrap procedure in which a matching random SNP was selected for each T2DM SNP from a GWAS. (See text for details.) *F*~ST~ values for T2DM/random markers are as follows: 0.138/0.129 (*P* = 0.79 for difference) for Pima and CHB, 0.163/0.158 (*P* = 0.83) for Pima and CEU, 0.232/0.241 (*P* = 0.80) for Pima and YRI, 0.147/0.146 (*P* = 0.99) for CEU and YRI, 0.187/0.185 (*P* = 0.95) for CHB and YRI, and 0.123/0.109 (*P* = 0.53) for CEU and CHB.](db141715f4){#F4}

Population Risk Attributable to T2DM Loci {#s14}
-----------------------------------------

Results for the calculation of GAF for Pimas compared with Europeans are shown in [Fig. 5*A*](#F5){ref-type="fig"}. The age-sex adjusted prevalence of T2DM was 48.2% in Pima Indians and 8.2% in non-Hispanic whites from NHANES (OR 10.5). The prevalence in Pimas adjusted to the frequency of risk alleles in CEU was slightly higher at 55.9%, resulting in a GAF of −0.19 (95% CI −0.34, −0.03); the low value of GAF reflects the lower value of the GRS in Pimas. When the 10 SNPs with statistically significant heterogeneity in the ORs were excluded from the calculation, GAF was −0.03 (−0.19, 0.08). Calculations were also conducted comparing non-Hispanic blacks in NHANES (*n* = 1,610, mean ± SD age 39.5 ± 20.1 years, 812 with diabetes) with non-Hispanic whites using allele frequencies derived from the African ancestry in the southwest U.S. (ASW) HapMap population. These analyses suggest that 66% of the excess prevalence in the black population is potentially attributable to allele frequency differences at these loci (GAF 0.66 \[95% CI 0.32, 1.07\]) ([Figure 5B](#F5){ref-type="fig"}).

![Calculation of the GAF in Pima Indians compared with non-Hispanic whites (NHW) from NHANES (left panel) and NHANES non-Hispanic blacks (NHB) compared with non-Hispanic whites (right panel). The age- and sex-adjusted prevalence of T2DM is shown on the *y*-axis for each group. The "adjusted" value represents the age- and sex-adjusted prevalence for the target population adjusted to the frequency of the risk alleles in the reference population across all 63 loci. The calculation comparing non-Hispanic blacks with non-Hispanic whites uses frequencies from the African ancestry in the southwest U.S. HapMap population, which may be more representative of African Americans than YRI.](db141715f5){#F5}

DISCUSSION {#s15}
==========

In recent years, many genetic variants reproducibly associated with T2DM have been identified. These have mostly been identified by GWAS in European populations. Many of these variants are also associated with T2DM in non-European populations, but there are instances of heterogeneity ([@B8],[@B10],[@B20]). The extent of association in high-risk populations, such as American Indians, is not well characterized. Our previous analyses in Pima Indians, with a much smaller number of SNPs, identified associations with SNPs in *FTO* and *KCNQ1* ([@B27],[@B28]); the *KCNQ1* associations are subject to parent-of-origin effects and are particularly strong in Pimas ([@B28]). *KLF14* variants also show parent-of-origin effects ([@B28]). Statistically significant heterogeneity between Pimas and Europeans at *TCF7L2* was also observed, and a multiallelic score from eight SNPs was modestly associated with T2DM in Pimas and with diminished insulin secretion ([@B20],[@B27]). In the present study, we have conducted a more complete survey of T2DM susceptibility variants in Pimas, including a total of 63 SNPs reproducibly associated with T2DM at genome-wide significance. These analyses identify additional SNPs that are nominally significantly associated with T2DM in Pimas in the same direction as in Europeans, including those in *GCKR, ZBED3, CDKAL1, ZFAND3, SPRY2, HMG20A*, and *PRC1.* Many of the T2DM susceptibility SNPs have effects in Pimas that are directionally consistent with those in Europeans, even if they were not individually statistically significant. Indeed, a multiallelic GRS that assesses effects of these variants in aggregate was statistically significant, even when SNPs with nominally significant effects or heterogeneity were excluded. The GRS was also strongly associated with diminished insulin secretion. Thus, the present findings suggest that the majority of T2DM-susceptibility variants do have modest effects on T2DM in this high-risk population but that some do not achieve statistical significance in the current sample size. Analyses in European populations suggest that the majority of T2DM-susceptibility variants influence T2DM risk through an effect on insulin secretion ([@B2],[@B47]), and the current analyses suggest that this is also the case in Pimas.

Despite general consistency for most SNPs between the direction of association with T2DM in Pimas and that observed in the original GWAS, there were several SNPs that showed evidence for heterogeneity in effect between Pimas and Europeans. In addition to *TCF7L2*, nominally significant heterogeneity was observed at *IRS1*,*ADAMTS9*,*ARL15*,*ZFAND3*,*PTPRD*,*C2CD4A*,*MPHOSPH9*,*SLC16A11*, and *DUSP9.* With the exception of *ZFAND3*, which has previously been described as associated in East Asians but not Europeans ([@B8]), the effect in Pimas was weaker than that in Europeans. Furthermore, the combined test of heterogeneity across all loci indicated that effects were generally weaker in Pimas than in Europeans (even when SNPs with nominally significant association or heterogeneity were excluded). Thus, while most T2DM-susceptibility variants do have an effect on T2DM risk in Pimas, this effect is generally not as strong as it is in Europeans. It is possible that, despite the large sample sizes, this heterogeneity reflects overestimation of effects in Europeans. Given that functional variants at most of these loci have not been identified, however, some heterogeneity between Europeans and other populations might be expected on account of differing linkage disequilibrium patterns. Indeed, fine-mapping studies have suggested that population heterogeneity at GWAS signals derived from Europeans is at least partly due to differences in linkage disequilibrium patterns ([@B18]).

Recent studies have described divergence in allele frequency at T2DM-susceptibility variants between major continental populations that is greater than expected given genetic distances between these populations and a gradient in genetic risk for T2DM with risk alleles at highest frequency in Africans and at lowest frequency in East Asians ([@B48],[@B49]). Such divergence in allele frequencies may reflect effects of natural selection in the different evolutionary histories of these populations. Prevalence of T2DM among Pima Indians is among the highest reported in the world, and if such evolutionary factors are responsible for this high prevalence, one might expect to see established T2DM risk alleles at high frequency in Pimas. The present analyses are consistent with previous studies, conducted with fewer SNPs ([@B48]), in that we observed the highest genetic risk scores in Africans (YRI) and the lowest in East Asians (CHB). However, genetic risk scores in Pimas were not particularly high and were comparable with, or lower than, those from low-risk populations, such as Europeans. The population differences in GRS observed here could reflect effects of genetic drift or natural selection. One study found that the Africa--East Asia gradient was greater than expected with random markers ([@B49]), which suggests natural selection, but a recent study that analyzed several global populations at 65 established T2DM-susceptibility loci suggested that T2DM-susceptibility alleles are generally evolutionarily neutral ([@B50]). Further work is needed to determine whether the high genetic risk scores for T2DM in African versus Asian populations is reflective of genetic drift or natural selection. However, in the present general analysis of genetic distances, we did not observe significant excess in the divergence between Pimas and other continental populations across established T2DM-susceptibility variants. This suggests that any overall effects of natural selection at these variants do not appear to have contributed to the high risk of T2DM in Pimas.

Regardless of the mechanisms by which population differences in risk allele frequency have arisen, such differences could explain population differences in prevalence of T2DM. The present analyses of GAF, however, suggest that differences in allele frequency at these established T2DM variants account for little of the increased population risk for T2DM in Pimas compared with European Americans. GWAS within Amerindian-derived populations may identify variants that are more likely to explain these population differences. Our recent GWAS comparing Pimas with young-onset T2DM to older nondiabetic individuals found association with a variant in *DNER* in Pimas but not in Europeans ([@B45]); this variant (rs1861612) shows little difference in allele frequency, however. A recent study suggested that the risk allele of rs75493593 in *SLC16A11*, which is more common in American Indians than Europeans, could explain ∼20% of the excess risk in Mexican Americans compared with European Americans, ignoring the effects of all other loci ([@B16]). In the present study, we found that the risk allele at *SLC16A11* is much more common in Pima Indians than in Europeans; however, its effect is outweighed by other variants at which the risk allele is less common Pimas, such that the overall extent to which established T2DM risk alleles can account for the excess prevalence in Pimas is negligible. In contrast, the present analyses suggest that 66% of the difference in T2DM prevalence between African Americans and European Americans is potentially attributable to allele frequency differences at these loci. Since transferability of European-derived T2DM variants to African Americans is somewhat uncertain given the highly divergent linkage disequilibrium patterns, the validity of the assumption that European-derived ORs represent causal effects may be questionable. Nonetheless, in light of the high proportion of excess prevalence between African Americans and Europeans that is attributable to differences in allele frequency at established T2DM variants, the fact that they account for none of the excess T2DM prevalence in Pimas seems remarkable.

In summary, the present analyses suggest that established T2DM variants are largely transferrable to high-risk populations, such as Pima Indians, albeit with weaker effects than in Europeans. However, differences in allele frequency across these established T2DM alleles account for little, if any, of the high T2DM prevalence in Pimas compared with populations of European ancestry. Thus, the high prevalence of T2DM in Pimas is likely the result of environmental factors or of genetic factors that remain largely unidentified.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db14-1715/-/DC1>.
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